Meena
Mallipeddi

AmplifyMD is not another telehealth app bolted onto a hospital's website. It is an EHR-integrated, multi-specialty virtual care platform paired with a national physician network. It plugs directly into the systems hospitals already run on - Epic among them - so a remote infectious disease doctor or cardiologist or neurologist works inside the same chart as the staff standing at the bedside. The platform now powers more than 300 programs across 150+ clinical sites, drawing on a network of nearly 300 physicians spread across 15 or more specialties.

The pitch is unglamorous and precise. Hospitals everywhere face the same shortage: not enough specialists, especially in emergency, inpatient, and rural settings. The old fix was to transfer the patient somewhere bigger, run more tests, and absorb the cost and delay. Mallipeddi's bet is that a full-stack coverage model - software plus a deep roster of credentialed doctors, available synchronously or asynchronously - closes that gap without forcing every hospital to hire specialists it cannot find or afford.

She keeps the company pointed at three numbers. "We're really focused on three objectives," she has said: "time to clinical decision, the quality of that decision and the user experience." It is the language of someone who used to read companies for a living and learned to distrust everything that could not be measured.

Mallipeddi grew up inside the profession she would later try to rewire. Her family was full of physicians, and the dinner-table conversation was often a quiet inventory of the system's failures: patients lost to a missing referral, transfers that should never have happened, tests ordered because nobody could reach the right specialist in time. Those were not abstractions to her. They were the recurring frustrations of people she loved, watching medicine bend around its own gaps.

Her co-founder is her husband, Anand Nathan, who came from a similar background. The two of them kept circling the same question - the one that now reads like a company mission statement - about why healthcare alone seemed immune to the efficiency that had reshaped every other industry. In 2019 they stopped asking and started building. Mallipeddi names Nathan as her single greatest professional influence, crediting him with the empathy, people leadership, and product vision that balance her own results-first instincts.

Founders of healthcare companies usually arrive from medicine or from software. Mallipeddi arrived from the markets. She studied International Relations with honors at Stanford, with a minor in Computer Science, then went to the University of Cambridge as a Gates Scholar for an M.Phil in Technology Policy at the Judge Business School. The Gates Scholarship - endowed by the Bill & Melinda Gates Foundation - is the kind of credential that tends to point people toward governments and think tanks. She went toward spreadsheets instead.

She started as an Associate Consultant at Bain & Company, then spent years on the buy-side as an equity analyst, first at Wyper Capital and later at Royce & Associates, hunting for technology and healthcare stocks worth owning anywhere in the world. By 2012 she was investing privately in the same sectors. All told, roughly fifteen years went into the discipline of judging other people's companies before she decided the more interesting move was to be judged. That investor's eye still shows up in how she runs AmplifyMD - in the obsession with decision time, in the refusal to let a metric drift.

In September 2025, AmplifyMD closed a $20 million Series B led by Forerunner Ventures, with participation from F-Prime Capital, Greylock, Tau Ventures, and Memorial Hermann Health System. That last name is the tell. Memorial Hermann does not just hold equity - it runs the platform, using AmplifyMD to fill infectious-disease gaps and slotting it directly into Epic. A health system putting money in alongside its own daily reliance is the rare kind of endorsement that cannot be spun. The round brought the company's total raised to $43 million.

The money is pointed at AI and clinical-workflow capabilities, deeper health-system partnerships, and a wider geographic footprint - particularly the underserved communities where the specialist gap is widest. The quieter math is what hospitals care about: AmplifyMD says its model can shave anywhere from half a day to a full day off a patient's length of stay, which translates to thousands of dollars per patient and beds that open back up.

Ask her about leadership and the answer is unsentimental. She describes herself as direct and transparent - quick to credit the team for what works and quicker still to name what is not working and fix it now rather than later. It is a style with the fingerprints of her old job all over it: the analyst who learned that a problem ignored does not get smaller, it compounds.

The recognition has followed the results. AmplifyMD has been named Best Overall Telemedicine Platform by MedTech Breakthrough in back-to-back years, landed on the Inc. 5000, and put Mallipeddi on lists of health-tech CEOs to watch and Inc.'s roster of female founders. She has become a sought-after voice on virtual care strategy and the clinician workforce crunch - the structural problem she has spent years refusing to accept as permanent.

Strip away the funding rounds and the awards, and the ambition is almost stubbornly simple: make it easier for a patient to see the right specialist sooner. Mallipeddi wants the full-stack, AI-enabled version of that promise - software and physicians together - reaching the hospitals and the communities that the old system kept skipping. She came up watching her own family bump against healthcare's broken edges. The company she built is, in the end, an argument that those edges were never inevitable.